



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Andras Szasz
Szasz.Andras@gek.szie.hu

SPECIALTY SECTION
This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Immunology

RECEIVED 09 November 2022
ACCEPTED 10 November 2022
PUBLISHED 22 November 2022

CITATION
Masaud SM, Szasz O, Szasz AM, Ejaz H,
Anwar RA and Szasz A (2022)
Corrigendum: A potential
bioelectromagnetic method to slow
down the progression and prevent the
development of ultimate pulmonary
fibrosis by COVID-19.
Front. Immunol. 13:1094086.
doi: 10.3389/fimmu.2022.1094086

COPYRIGHT
© 2022 Masaud, Szasz, Szasz, Ejaz,
Anwar and Szasz. This is an open-
access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: A potential bioelectromagnetic method to slow down the progression and prevent the development of ultimate pulmonary fibrosis by COVID-19

Syed Muzzammil Masaud¹, Oliver Szasz², A. Marcell Szasz³,
Huma Ejaz⁴, Rana Attique Anwar⁵ and Andras Szasz^{2*}

¹OncoTreatments Pvt Ltd, Karachi, Pakistan, ²Biotechnics Department, St. Istvan University, Godollo, Hungary, ³Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary, ⁴Department of Biochemistry, University of Turku, Turku, Finland, ⁵Department of Oncology, Nishtar Medical College Multan, Multan, Pakistan

KEYWORDS

SARS-CoV-21, rehabilitation, electric field, immune-effect, heat-shock protein, modulated electro-hyperthermia

A corrigendum on

A potential bioelectromagnetic method to slow down the progression and prevent the development of ultimate pulmonary fibrosis by COVID-19

by Masaud SM, Szasz O, Szasz AM, Ejaz H, Anwar RA and Szasz A (2020) *Front. Immunol.* 11:556335. doi: 10.3389/fimmu.2020.556335

In the published article, there was an error in the Conflict of Interest statement. “SM was employed by the company OncoTreatments Pvt Ltd. AS declares that he is the Chief Scientific Officer of Oncotherm Kft. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.” The correct Conflict of Interest appears below.

In the published article, there was an error in the Funding statement. Missing grant supporting this manuscript. The correct Funding statement appears below.

Funding

This work was not supported by a company, but it was supported by the Hungarian Ministry of Finance grant: PM/15237-13/2020.

Conflict of interest

SM was employed by the company OncoTreatments Pvt Ltd. AS declares that he is the Chief Scientific Officer of Oncotherm Kft./GmbH. OS declares that he is employed by Oncotherm Kft./GmbH.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.